CardiaTec Biosciences is a TechBio company focused on advancing the understanding and treatment of cardiovascular diseases through the integration of large-scale multiomics data. The company is in the process of creating the largest human cardiac tissue multiomics database by collaborating with a network of hospitals and academic institutions. This initiative aims to address the complexities of cardiovascular disease biology, which has historically hindered clinical translation and investment in research. By leveraging advanced computational modeling techniques, CardiaTec seeks to navigate high-dimensional data encompassing various biological layers, including genomics, epigenomics, transcriptomics, and proteomics.

The platform developed by CardiaTec is designed to facilitate the discovery and development of novel therapeutics for cardiovascular conditions. By generating high-quality, unbiased multiomics data, the company aims to uncover the intricate mechanisms that drive disease progression. This proprietary data strategy not only enhances the understanding of cardiovascular biology but also supports the identification of innovative therapeutic targets, ultimately contributing to improved patient outcomes in a field that significantly impacts global health.

United Kingdom

CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease.

We leverage large and high-dimensional human omics data to better navigate complex disease biology to discover novel and differentiated therapeutics. 

CardiaTec Biosciences

Company Details